Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3009120 + LY3214996 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3009120 | DP-4978 | RAF Inhibitor (Pan) 28 | LY3009120 is a Pan-RAF inhibitor that inhibits signaling of all RAF isoforms and RAF dimers, which leads to inhibition of tumor cell growth (PMID: 26343583, PMID: 28576749). | |
LY3214996 | Temuterkib|LY-3214996|LY 3214996 | ERK Inhibitor (pan) 21 | LY3214996 inhibits ERK1/2, potentially resulting in decreased growth of tumors with alterations in the RAS/MAPK pathway (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4973, PMID: 31744895). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61H | rhabdomyosarcoma | sensitive | LY3009120 + LY3214996 | Preclinical - Cell culture | Actionable | In a preclinical study, LY3214996 and LY3009120 combination treatment synergistically induced cell cycle arrest and apoptosis in rhabdomyosarcoma cell lines harboring NRAS Q61H in culture (PMID: 34737198). | 34737198 |
HRAS Q61K | rhabdomyosarcoma | sensitive | LY3009120 + LY3214996 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, LY3214996 and LY3009120 combination treatment synergistically induced cell cycle arrest and apoptosis in rhabdomyosarcoma cell lines harboring HRAS Q61K in culture and induced tumor growth regression in a xenograft model (PMID: 34737198). | 34737198 |
NRAS Q61L | rhabdomyosarcoma | sensitive | LY3009120 + LY3214996 | Preclinical - Cell culture | Actionable | In a preclinical study, LY3214996 and LY3009120 combination treatment synergistically induced cell cycle arrest and apoptosis in rhabdomyosarcoma cell lines harboring NRAS Q61L in culture (PMID: 34737198). | 34737198 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|